COVID-19 Vaccination Coverage, by Race and Ethnicity - National Immunization Survey Adult COVID Module, United States, December 2020-November 2021.
Journal
MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Some racial and ethnic minority groups have experienced disproportionately higher rates of COVID-19-related illness and mortality (1,2). Vaccination is highly effective in preventing severe COVID-19 illness and death (3), and equitable vaccination can reduce COVID-19-related disparities. CDC analyzed data from the National Immunization Survey Adult COVID Module (NIS-ACM), a random-digit-dialed cellular telephone survey of adults aged ≥18 years, to assess disparities in COVID-19 vaccination coverage by race and ethnicity among U.S. adults during December 2020-November 2021. Asian and non-Hispanic White (White) adults had the highest ≥1-dose COVID-19 vaccination coverage by the end of April 2021 (69.6% and 59.0%, respectively); ≥1-dose coverage was lower among Hispanic (47.3%), non-Hispanic Black or African American (Black) (46.3%), Native Hawaiian or other Pacific Islander (NH/OPI) (45.9%), multiple or other race (42.6%), and American Indian or Alaska Native (AI/AN) (38.7%) adults. By the end of November 2021, national ≥1-dose COVID-19 vaccination coverage was similar for Black (78.2%), Hispanic (81.3%), NH/OPI (75.7%), and White adults (78.7%); however, coverage remained lower for AI/AN (61.8%) and multiple or other race (68.0%) adults. Booster doses of COVID-19 vaccine are now recommended for all adults (4), but disparities in booster dose coverage among the fully vaccinated have become apparent (5). Tailored efforts including community partnerships and trusted sources of information could be used to increase vaccination coverage among the groups with identified persistent disparities and can help achieve vaccination equity and prevent new disparities by race and ethnicity in booster dose coverage.
Identifiants
pubmed: 35679179
doi: 10.15585/mmwr.mm7123a2
pmc: PMC9181054
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
757-763Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Références
Ann Intern Med. 2021 Mar;174(3):362-373
pubmed: 33253040
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1735-1739
pubmed: 34914672
MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):991-996
pubmed: 34264909
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):459-465
pubmed: 35324878
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1545-1552
pubmed: 34735422
Lancet Reg Health Am. 2022 Jun;10:100220
pubmed: 35262038
MMWR Morb Mortal Wkly Rep. 2022 Apr 29;71(17):601-605
pubmed: 35482556
Am J Epidemiol. 2020 Nov 2;189(11):1244-1253
pubmed: 32619007